Daniel G. Rendeiro

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Daniel G. Rendeiro sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials none currently recruiting 1 completed upper half by trial count

Daniel G. Rendeiro: 1 sponsored US clinical trial, none currently recruiting.

Daniel G. Rendeiro sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. The most-studied condition in this pipeline is Shoulder Adhesive Capsulitis, with 1 trials.

Mid-pack sponsor footprint

Daniel G. Rendeiro is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

1 total, page 1 of 1

COMPLETED NA

Translational Manipulation Under Interscalene Block for Adhesive Capsulitis of the Shoulder (TMACS)

NCT03090555

Therapeutic Areas

Shoulder Adhesive Capsulitis 1
Adhesive Capsulitis of Shoulder 1
Frozen Shoulder 1

How the Daniel G. Rendeiro archive is shaped

1 indexed studies, none listed as recruiting (0% open); 1 completed (100%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Shoulder Adhesive Capsulitis (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Daniel G. Rendeiro: archived-pipeline peers nationwide

Peers matched on 1 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Daniel G. Rendeiro sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Daniel G. Rendeiro1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Daniel G. Rendeiro sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Daniel G. Rendeiro sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Daniel G. Rendeiro page

1 registered trials is a research-attention snapshot, not an endorsement of Daniel G. Rendeiro or any single study.

  • None of Daniel G. Rendeiro's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Shoulder Adhesive Capsulitis is the condition Daniel G. Rendeiro studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Shoulder Adhesive Capsulitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Daniel G. Rendeiro pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.